Mobile phone apps for the prediction of prostate cancer: External validation of the Coral and Rotterdam apps
Authors:
- Cosimo De NunzioCNCosimo De Nunzio
- Riccardo LombardoRiccardo Lombardo
- Giorgia TemaGTGiorgia Tema
- Fabiana CancriniFCFabiana Cancrini
- Giorgio Ivan RussoGiorgio Ivan Russo
- Rodrigo ChaconRCRodrigo Chacon
- Eduard Garcia-CruzEGEduard Garcia-Cruz
- Maria Jose RibalMRMaria Jose Ribal
- Giuseppe MorgiaGiuseppe Morgia
- Antonio AlcarazAAAntonio Alcaraz
- Andrea TubaroATAndrea Tubaro
- 1 March 2019
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (3) , 471-476
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- Can Mobile Phone Apps Influence People’s Health Behavior Change? An Evidence ReviewJournal of Medical Internet Research, 2016
- Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysisAnnals of Oncology, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low- vs High-grade Prostate CancerUrology, 2014
- Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative groupWorld Journal of Urology, 2011
- Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsyThe Prostate, 2011
- PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests?European Urology, 2008
- Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention TrialJNCI: Journal of the National Cancer Institute, 2006
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004